You are here

  • Home
  • Archive
  • Volume 10, Issue 6
  • Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade

Article info

Article menu

This article has a correction. Please see:

Oncolytic and local immunotherapy
Original research
Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade

Authors

  • Fei Ju State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Yong Luo Yangshengtang Co., Ltd, Hangzhou, ChinaHangzhou Yangshengtang Biopharmaceutical Co., Ltd, Hangzhou, China PubMed articlesGoogle scholar articles
  • Chaolong Lin State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Xian Jia School of Life Sciences, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Zilong Xu State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Rui Tian State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Yanhua Lin State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Min Zhao State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, ChinaSchool of Life Sciences, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Yating Chang State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, ChinaSchool of Life Sciences, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Xiaoxuan Huang State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Shaopeng Li State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Wenfeng Ren State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Yaning Qin State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Mengqin Yu State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Jizong Jia Beijing Wantai Biological Pharmacy, Beijing, China PubMed articlesGoogle scholar articles
  • Jinle Han Beijing Wantai Biological Pharmacy, Beijing, China PubMed articlesGoogle scholar articles
  • Wenxin Luo State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Jun Zhang State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Guo Fu School of Medicine, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Xiangzhong Ye Beijing Wantai Biological Pharmacy, Beijing, China PubMed articlesGoogle scholar articles
  • Chenghao Huang State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Ningshao Xia State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, ChinaSchool of Life Sciences, Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles

Citation

Ju F, Luo Y, Lin C, et al
Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade
Journal for ImmunoTherapy of Cancer 2022;10:e004762. doi: 10.1136/jitc-2022-004762
Online issue publication 
March 20, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.